ada standards of care 2025 obesity pharmacotherapy glp-1 recommendations Agonists Weight Loss Drugs Market Report, 2025-2030 GLP-1 agonists and changes in

Caloric restriction, body image changes, and metabolic shifts during substantial weight reduction may affect neurotransmitter balance involved in mood regulation

Interleukin 6 Next to TNF, the cytokine IL-6 possesses the best-documented impact on incretin hormone secretion

Tirzepatide, approved by the FDA in 2022, faces a similar patent landscape with exclusivity expected to extend through 2037 or later

If no significant immunogenicity risk is observed, the impurity can be controlled at 0.5% by testing each batch

The combination of Ozempic and cannabis raises questions about how these substances might interact within the body